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Summary and Implications 
 VRP were constructed that co-express porcine 
reproductive and respiratory syndrome virus (PRRSV) GP5 
and M proteins and form a heterodimer. This co-expressing 
VRP is an attractive candidate for a novel PRRSV vaccine 
based on previous work with equine arteritis virus (EAV). 
 
Introduction 
 Virus-like replicon particles (VRP) derived from the 
alphavirus Venezuelan equine encephalitis (VEE) is a single 
cycle vector not capable of propagating past the initial cell 
infected. VRP have been previously used to show that co-
expression of the GL and M proteins of EAV are required 
for protection. We have recently developed VRP co-
expressing GP5 and M proteins of PRRSV, however there 
are no previous reports of immunizing swine with VRP 
vaccines. The purpose of this study was to determine the 
potential for using VRP vaccines in pigs. 
 
Materials and Methods 
 VRPs were constructed as expressing PRRSV proteins. 
The PRRSV ORF5 and ORF6 genes were cloned into 
replicon vectors individually. Replicons that produced the 
correct sized subgenomic transcripts and at the highest level 
were chosen to generate double subgenomic replicons co-
expressing both (Figure 1). Replicons were analyzed by IFA, 
Western blot, and northern blot. Each replicon was then 
packaged into a VRP by supplying alphavirus structural 
proteins in trans. VRP were incubated for 18 hours on Vero 
cells followed by cell lysis and Western blot analysis. 
 
Results and Discussion 
 Analysis of replicons indicated that constructs were 
producing the correct sized subgenomic transcripts and 
correct PRRSV proteins detected by PRRSV convalescent 
pig serum. Western blot analysis of Vero cell lysates 
indicated that the VRP co-expressed the GP5 and M 
monomers as well as the GP5-M heterodimer (Figure 2).  
 VRP can co-express PRRSV GP5 and M proteins in 
heterodimer form. This work supports the in vivo evaluation 
of GP5-M VRP as a novel vaccine for PRRSV. Vaccination-
challenge trials in pigs are in progress. 
 
Figure 1. Design of replicon co-expressing PRRSV GP5 
and M proteins. 
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Figure 2. Non-reduced western blot. Lane 1: ladder, 
Lane 2: co-expressed GP-M, Lane 3: neg control 
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